EGFL7 antibody
Principal name
EGFL7 antibody
Alternative names for EGFL7 antibody
EGF-like protein 7, EGF like protein 7, VE-statin, NOTCH4-like protein, Zneu1, MEGF7, UNQ187, PRO1449, Epidermal growth factor-like protein 7, Multiple epidermal growth factor-like domains protein 7, Multiple EGF-like domains protein 7, Vascular endothelial statin
Ncbi ID
9606, NP_057299.1, NP_057299, NP_001158036.1, NM_001164564, NM_139104
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Immunocytochemistry/Immunofluorescence (ICC/IF), Frozen Sections (C), Immunoprecipitation (IP), Paraffin Sections (P)
Background of EGFL7 antibody
EGFL7 (epidermal growth factor-like domain 7) is a secreted angiogenic factor that is highly conserved in vertebrates. Most secreted angiogenic signaling molecules, including VEGF and FGF-2, are mainly expressed by non-endothelial cell types such as fibroblasts. In contrast, EGFL7 is unique because it is almost exclusively expressed by and acts on endothelial cells. EGFL7 expression is highest when the endothelium is in an active, proliferating state. This factor acts as a chemo-attractant for endothelial cells and binds to components of the extracellular matrix. In vivo, EGFL7 is important for regulating tubulogenesis in Zebrafish and for controlling vascular patterning and integrity in mice. Its function in blood vessel development is mediated, at least in part, through modulation of Notch signaling. There is evidence that support a role for EGFL7 in developmental and postnatal angiogenesis as well as a potential role for EGFL7 in vascular repair.
EGFL7, also known as VE-Statin (Vascular endothelial Statin), is a endothelial-specific protein that is a marker for progenitor, embryonic and adult endothelial cells. Mature soluble EGFL7/VE-Statin is a 41 kDa protein containing an N-terminal cysteine rich EMI domain, followed by two EGF-like domains and a coiled-coil region. EGFL7/VE-Statin inhibits PDGF-BB-induced smooth muscle cell migration. The amino acid sequence of human EGFL7/VE-Statin is 80% identical to that of mouse EGFL7/VE-Statin.
Detection limit for recombinant GST tagged EGFL7 is approximately 0.03ng/ml as a capture antibody.
Detection limit for recombinant GST tagged EGFL7 is approximately 3ng/ml as a capture antibody.
EGFL7 MaxPab rabbit polyclonal antibody. Western Blot analysis of EGFL7 expression in human placenta.
Western Blot analysis of EGFL7 expression in transfected 293T cell line (H00051162-T02) by EGFL7 MaxPab polyclonal antibody.Lane 1: EGFL7 transfected lysate(29.60 KDa).Lane 2: Non-transfected lysate.
EGFL7 MaxPab rabbit polyclonal antibody. Western Blot analysis of EGFL7 expression in A-431.
Immunohistochemical staining (ICC) of Human and Mouse EGFL7 constructs overexpressed in HEK293T cell with anti-human VE-Statin/EGFL-7 Antibody Cat.-No DP3521.
The experiment was performed by Dr. Mirko HH Schmidt, Institute of Neurology (Edinger Institute), Neuroscience Center, J.W. Goethe University Scholl of Medicine, Heinrich-Hoffmann-Str. 7, D-60528 Frankfurt, Germany.
The experiment was performed by Dr. Mirko HH Schmidt, Institute of Neurology (Edinger Institute), Neuroscience Center, J.W. Goethe University Scholl of Medicine, Heinrich-Hoffmann-Str. 7, D-60528 Frankfurt, Germany.
Immunohistochemistry staining of blood vessel endothelial cells in the white in Human brain with anti-Human VE-Statin/EGFL7 antibody (DP3521/DP3521S). The experiment was performed by Dr. Mirko HH Schmidt, Institute of Neurology (Edinger Institute), Neuroscience Center, J.W. Goethe University Scholl of Medicine, Heinrich-Hoffmann-Str.7, D-60528 Frankfurt, Germany.
Immunohistochemistry staining of blood vessel endothelial cells in the Human fetal brain with anti-Human VE-Statin/EGFL7 antibody (DP3521/DP3521S). The experiment was performed by Dr. Mirko HH Schmidt, Institute of Neurology (Edinger Institute), Neuroscience Center, J.W. Goethe University Scholl of Medicine, Heinrich-Hoffmann-Str.7, D-60528 Frankfurt, Germany.
EGFL7 MaxPab rabbit polyclonal antibody. Western Blot analysis of EGFL7 expression in human placenta.
Western Blot analysis of EGFL7 expression in transfected 293T cell line (H00051162-T02) by EGFL7 MaxPab polyclonal antibody.Lane 1: EGFL7 transfected lysate(29.60 KDa).Lane 2: Non-transfected lysate.
EGFL7 MaxPab rabbit polyclonal antibody. Western Blot analysis of EGFL7 expression in A-431.
Immunoprecipitation of EGFL7 transfected lysate using anti-EGFL7 MaxPab rabbit polyclonal antibody and Protein A Magnetic Bead (U0007), and immunoblotted with EGFL7 MaxPab mouse polyclonal antibody (B01) (H00051162-B01).
AP23785PU EGFL7 antibody staining of Human placenta.
Immunocytochemical staining (ICC) of human and mouse EGFL7: Left column: DAPI; Middle column: Staining with anti-mouse EGFL7 antibody Cat.-No. AP60004PU-N; Right column: Merge.
Performed by Dr. Frank Bicker, Research group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Performed by Dr. Frank Bicker, Research group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Western analysis of recombinant human and mouse EGFL7 using anti-mouse EGFL7 antibody Cat.-No. AP60004PU-N. There is no cross reactivity visible with human EGFL-7. Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Immunoprecipitation of human and mouse EGFL7 constructs with anti-mouse EGFL7 antibody Cat.-No. AP60004PU-N and subsequent Western analysis with anti-V5 antibodies. Samples were loaded in 15% SDS-polyacrylamide gel under reducing conditions.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Immunocytochemical staining (ICC) of human and mouse EGFL7: Left column: DAPI; Middle column: Staining with anti-human EGFL7 antibody Cat.-No. AP60007PU; Right column: Merge.
Performed by Dr. Frank Bicker, Research group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Performed by Dr. Frank Bicker, Research group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Western analysis of recombinant human and mouse EGFL7 using anti-human EGFL7 antibody Cat.-No. AP60007PU. There is no cross reactivity with the mouse EGFL7.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Immunoprecipitation of human and mouse EGFL7 constructs with anti-human EGFL7 antibody Cat.-No. AP60007PU and subsequent Western analysis with anti-V5 antibodies. Samples were loaded in 15% SDS-polyacrylamide gel under reducing conditions.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Immunocytochemical staining (ICC) of human and mouse EGFL7: Left column: DAPI; Middle column: Staining with antihuman EGFL7 antibody Cat.-No. AP60008PU; Right column: Merge. Performed by Dr. Frank Bicker, Research group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Western analysis of recombinant human and mouse EGFL7 using anti-human EGFL7 antibody Cat.-No. AP60008PU. There is no cross reactivity with the mouse EGFL7.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Immunoprecipitation of human and mouse EGFL7 constructs with anti-human EGFL7 antibody Cat.-No. AP60008PU and subsequent Western analysis with anti- V5 antibodies. Samples were loaded in 15% SDS-polyacrylamide gel under reducing conditions.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
Performed by Dr. Frank Bicker, Rresearch group „Molecular Signal Transduction“ (Prof. Dr. Mirko HH Schmidt), Institute of Microscopic Anatomy and Neurobiology, University Mainz, Germany.
SDS-PAGE analysis of recombinant human EGFL7 derived from insect cells Cat.-No. AR60007PU-N. Sample was loaded in 15% SDS-polyacrylamide gel under reducing condition and stained with Coomassie blue.
SDS-PAGE analysis of recombinant mouse EGFL7 derived from insect cells Cat.-No. AR60004PU-N. Sample was loaded in 15% SDS-polyacrylamide gel under reducing condition and stained with Coomassie blue.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY EGFL7 (RC218849, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-EGFL7.(1:2000)
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY EGFL7 (RC218849, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-EGFL7.(1:2000)
AP33497PU-N (1µg/ml) staining of Heart (A), Kidney (B) and Lung (C) lysates (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Predicted cell location: Cytoplasm. Positive control: Human thyroid cancer tissue. Recommended dilution: 1/25-100 The image on the left is immunohistochemistry of paraffin-embedded human thyroid cancer tissue using EGFL7 antibody at dilution 1/20, on the right is treated with the fusion protein. (Original magnification:x200)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA321850 | EGFL7 antibody |
||||||
| Anti-EGFL7 Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | E, P |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA807830 | EGFL7 antibody |
||||||
| EGFL7 mouse monoclonal antibody, clone OTI2B5 (formerly 2B5) | |||||||
 |
Mouse | IgG1 | OTI2B5 | Purified | Hu | WB |
0.1 ml /
€360.00
|
| OriGene Technologies, Inc. | |||||||
|
|||||||
| TA807846 | EGFL7 antibody |
||||||
| EGFL7 mouse monoclonal antibody, clone OTI4A5 (formerly 4A5) | |||||||
 |
Mouse | IgG1 | OTI4A5 | Purified | Hu | WB |
0.1 ml /
€360.00
|
| OriGene Technologies, Inc. | |||||||
|
|||||||
| AP33497PU-N | EGFL7 antibody |
||||||
 |
Goat | Aff - Purified | Hu | WB |
0.1 mg /
€380.00
|
||
| OriGene Technologies GmbH | |||||||
| AP60004PU-N | EGFL7 (C-term) antibody |
||||||
 |
Rabbit | IgG | Purified | Ms | ICC/IF, IP, WB |
0.1 mg /
€270.00
|
|
| OriGene Technologies GmbH | |||||||
 +2 additional images |
|||||||
| AP60007PU-N | EGFL7 (C-term) antibody |
||||||
 |
Rabbit | IgG | Purified | Hu | C, ICC/IF, IP, WB |
0.1 mg /
€270.00
|
|
| OriGene Technologies GmbH | |||||||
| +2 additional images |
|||||||
| AP60008PU-L | EGFL7 (C-term) antibody |
||||||
 |
Rabbit | IgG | Purified | Hu | C, ICC/IF, IP, WB |
0.2 mg /
€370.00
|
|
| OriGene Technologies GmbH | |||||||
| +2 additional images |
|||||||
| AP60008PU-N | EGFL7 (C-term) antibody |
||||||
|
Rabbit | IgG | Purified | Hu | C, ICC/IF, IP, WB |
0.1 mg /
€270.00
|
|
| OriGene Technologies GmbH | |||||||
| +2 additional images |
|||||||
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP318849 | EGFL7 (transcript variant 1) |
||||
| Purified recombinant protein of Homo sapiens EGF-like-domain, multiple 7 (EGFL7), transcript variant 1 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
| AR31184PU-N | Interleukin-35 (IL35) |
||||
 |
Human | Purified | > 90 % pure by SDS-PAGE gel and HPLC analyses | HEK293 cells |
10 µg /
€250.00
|
| OriGene Technologies GmbH | |||||
| AR31184PU-S | Interleukin-35 (IL35) |
||||
|
Human | Purified | > 90 % pure by SDS-PAGE gel and HPLC analyses | HEK293 cells |
2 µg /
€140.00
|
| OriGene Technologies GmbH | |||||
Mouse Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| MR203689L2V | Lenti ORF particles, Egfl7 (GFP-tagged) - Mouse EGF-like domain 7 (Egfl7), transcript variant d, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,240.00
|
|
| OriGene Technologies, Inc. | ||
| MR203689L1V | Lenti ORF particles, Egfl7 (Myc-DDK-tagged) - Mouse EGF-like domain 7 (Egfl7), transcript variant d, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€1,110.00
|
|
| OriGene Technologies, Inc. | ||
Rat Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RR210981L2V | Lenti ORF particles, Egfl7 (GFP-tagged ORF) - Rat EGF-like-domain, multiple 7 (Egfl7), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€930.00
|
|
| OriGene Technologies, Inc. | ||
| RR210981L1V | Lenti ORF particles, Egfl7 (Myc-DDK-tagged ORF) - Rat EGF-like-domain, multiple 7 (Egfl7), 200 uL, >10^7 TU/mL |
|
|
200 µl /
€830.00
|
|
| OriGene Technologies, Inc. | ||